AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
297.05B
Market cap297.05B
Price-Earnings ratio
28.11
Price-Earnings ratio28.11
Dividend yield
1.67%
Dividend yield1.67%
Average volume
1.88M
Average volume1.88M
High today
$191.13
High today$191.13
Low today
$188.46
Low today$188.46
Open price
$189.32
Open price$189.32
Volume
1.64M
Volume1.64M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

AstraZeneca(AZN) stock is priced at $191.12, giving the company a market capitalization of 297.05B. It carries a P/E multiple of 28.11 and pays a dividend yield of 1.67%.

On 2026-06-29, AstraZeneca(AZN) stock traded between a low of $188.46 and a high of $191.13. Shares are currently priced at $191.12, which is +1.4% above the low and -0.0% below the high.

AstraZeneca(AZN) shares are trading with a volume of 1.64M, against a daily average of 1.88M.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

In the last year, AstraZeneca(AZN) shares hit a 52-week high of $212.71 and a 52-week low of $137.23.

AZN News

Benzinga 10h
AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe

Efzimfotase Alfa Meets Primary And Secondary Endpoints In HPP Trial Patients treated with efzimfotase alfa achieved a median Radiographic Global Impression of...

AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe
TipRanks 10h
AstraZeneca Advances AI-Driven Lung Cancer Risk Study in Brazil

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

TipRanks 10h
AstraZeneca Updates Phase 1 Acalabrutinib Data in Japan: What Investors Should Watch

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for mor...

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
10.3%
Sell
6.9%

More AZN News

TipRanks 17h
AstraZeneca announces Enhertu approval in EU for HER2 positive solid tumors

Enhertu has been approved in the European Union, or EU, as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive solid...

TipRanks 20h
AstraZeneca and Daiichi Sankyo win EU tumour‑agnostic approval for Enhertu

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 3d
AstraZeneca Advances BRAVO Trial for AZD2389 in Advanced Liver Fibrosis

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

Nasdaq 4d
Astrazeneca Ascends While Market Falls: Some Facts to Note

Astrazeneca (AZN) closed at $96.34 in the latest trading session, marking a +1.94% move from the prior day. The stock outperformed the S&P 500, which registered...

Astrazeneca Ascends While Market Falls: Some Facts to Note
TipRanks 4d
AstraZeneca’s ARG iNAUT IPF Trial Puts New Respiratory Bet on Investors’ Radar

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

TipRanks 4d
AstraZeneca Backs Brazil Lung Cancer Screening Study With Long-Term Market Edge Potential

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

TipRanks 4d
AstraZeneca’s Tozorakimab COPD Study Reaches Key Long-term Milestone

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for mor...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.